Rapid up-regulation of cyclooxygenase-2 by 5-fluorouracil in human solid tumors

Stuart J. Mercer, Federica Di Nicolantonio, Louise A. Knight, Francis G. Gabriel, Pauline A. Whitehouse, Sanjay Sharma, Augusta Fernando, Pradeep Bhandari, Shaw S. Somers, Simon K. Toh, Ian A. Cree

Research output: Contribution to journalArticlepeer-review


Inhibition of cyclooxygenase (COX)-2 has been associated with reduced growth of malignant cells. Current therapy of gastrointestinal carcinomas involves the use of 5-fluorouracil (5-FU)-based chemotherapy and we have therefore studied the effect of this agent on the expression of COX-2. COX-2 expression was measured by quantitative RT-PCR in biopsies from a series of 14 esophageal carcinomas, six of which had paired samples taken before and after chemotherapy, and in tumor-derived cells exposed to 5-FU in vitro from a series of 44 tumors, including breast, ovarian, esophageal and colonic carcinomas. COX-2 expression was increased by exposure to 5-FU or 5-FU combination chemotherapy in all the tumor types studied, whether measured in biopsies taken before and after 5-FU-based chemotherapy (4-fold increase, p

Original languageEnglish
Pages (from-to)495-500
Number of pages6
JournalAnti-Cancer Drugs
Issue number5
Publication statusPublished - May 2005


  • 5-fluorouracil
  • Chemotherapy
  • Colon
  • Cyclooxygenase-2
  • Esophageal cancer
  • Irinotecan

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology


Dive into the research topics of 'Rapid up-regulation of cyclooxygenase-2 by 5-fluorouracil in human solid tumors'. Together they form a unique fingerprint.

Cite this